Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Patterns of persistent genital human papillomavirus infection among women worldwide: a literature review and meta-analysis.

Rositch AF, Koshiol J, Hudgens MG, Razzaghi H, Backes DM, Pimenta JM, Franco EL, Poole C, Smith JS.

Int J Cancer. 2013 Sep 15;133(6):1271-85. doi: 10.1002/ijc.27828. Epub 2012 Oct 11. Review.

2.

The clearance of oral high-risk human papillomavirus infection is impaired by long-term persistence of cervical human papillomavirus infection.

Louvanto K, Rautava J, Syrjänen K, Grénman S, Syrjänen S.

Clin Microbiol Infect. 2014 Nov;20(11):1167-72. doi: 10.1111/1469-0691.12700. Epub 2014 Jul 12.

3.

A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion.

Plummer M, Schiffman M, Castle PE, Maucort-Boulch D, Wheeler CM; ALTS Group.

J Infect Dis. 2007 Jun 1;195(11):1582-9. Epub 2007 Apr 16.

PMID:
17471427
4.

Spectrum of genital human papillomavirus infection in a female adolescent population.

Jamison JH, Kaplan DW, Hamman R, Eagar R, Beach R, Douglas JM Jr.

Sex Transm Dis. 1995 Jul-Aug;22(4):236-43.

PMID:
7482107
5.

Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis.

Koshiol J, Lindsay L, Pimenta JM, Poole C, Jenkins D, Smith JS.

Am J Epidemiol. 2008 Jul 15;168(2):123-37. doi: 10.1093/aje/kwn036. Epub 2008 May 15. Review.

6.

Natural history of cervicovaginal papillomavirus infection in young women.

Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD.

N Engl J Med. 1998 Feb 12;338(7):423-8.

7.

Natural history of anal human papillomavirus infection in heterosexual women and risks associated with persistence.

Moscicki AB, Ma Y, Farhat S, Jay J, Hanson E, Benningfield S, Jonte J, Godwin-Medina C, Wilson R, Shiboski S.

Clin Infect Dis. 2014 Mar;58(6):804-11. doi: 10.1093/cid/cit947. Epub 2013 Dec 23.

8.

Incidence, duration, and reappearance of type-specific cervical human papillomavirus infections in young women.

Insinga RP, Perez G, Wheeler CM, Koutsky LA, Garland SM, Leodolter S, Joura EA, Ferris DG, Steben M, Brown DR, Elbasha EH, Paavonen J, Haupt RM; FUTURE I Investigators.

Cancer Epidemiol Biomarkers Prev. 2010 Jun;19(6):1585-94. doi: 10.1158/1055-9965.EPI-09-1235.

9.

Evaluation of type-specific HPV persistence and high-risk HPV viral load quantitation in HPV positive women under 30 with normal cervical cytology.

Carcopino X, Bolger N, Henry M, Mancini J, Boubli L, Olive D, Cleary S, Prendiville W, Tamalet C.

J Med Virol. 2011 Apr;83(4):637-43. doi: 10.1002/jmv.22022.

PMID:
21328378
10.

Epidemiological data of different human papillomavirus genotypes in cervical specimens of HIV-1-infected women without history of cervical pathology.

Videla S, Darwich L, Cañadas MP, Paredes R, Tarrats A, Castella E, Llatjos M, Bofill M, Clotet B, Sirera G; HIV-HPV Study Group.

J Acquir Immune Defic Syndr. 2009 Feb 1;50(2):168-75. doi: 10.1097/QAI.0b013e3181938e63.

PMID:
19131892
11.

Prevalence of human papillomavirus in women attending cervical screening in the UK and Ireland: new data from northern Ireland and a systematic review and meta-analysis.

Anderson L, O'Rorke M, Jamison J, Wilson R, Gavin A; HPV Working Group members.

J Med Virol. 2013 Feb;85(2):295-308. doi: 10.1002/jmv.23459. Epub 2012 Nov 14. Review.

PMID:
23161367
12.
13.

A longitudinal study of HPV detection and cervical pathology in HIV infected women.

Cubie HA, Seagar AL, Beattie GJ, Monaghan S, Williams AR.

Sex Transm Infect. 2000 Aug;76(4):257-61.

14.

Pre-vaccination prevalence of infections with 25 non-high-risk human papillomavirus types among 1,000 Slovenian women in cervical cancer screening.

Učakar V, Poljak M, Oštrbenk A, Klavs I.

J Med Virol. 2014 Oct;86(10):1772-9. doi: 10.1002/jmv.23997. Epub 2014 Jun 30.

PMID:
24978445
15.

Viral determinants of human papillomavirus persistence following loop electrical excision procedure treatment for cervical intraepithelial neoplasia grade 2 or 3.

Kreimer AR, Katki HA, Schiffman M, Wheeler CM, Castle PE; ASCUS-LSIL Triage Study Group.

Cancer Epidemiol Biomarkers Prev. 2007 Jan;16(1):11-6.

16.

Incidence and duration of cervical human papillomavirus 6, 11, 16, and 18 infections in young women: an evaluation from multiple analytic perspectives.

Insinga RP, Dasbach EJ, Elbasha EH, Liaw KL, Barr E.

Cancer Epidemiol Biomarkers Prev. 2007 Apr;16(4):709-15.

17.

A 7.5-year prospective study of longer than 18 months type-specific human papillomavirus persistence in a routine cytology-based cervical screening population of about 31,000 women in West Germany.

Kovács K, Varnai AD, Bollmann M, Bankfalvi A, Szendy M, Speich N, Schmitt C, Pajor L, Bollmann R, Hildenbrand R.

Eur J Cancer Prev. 2009 Aug;18(4):307-15. doi: 10.1097/CEJ.0b013e328324061a.

PMID:
19436214
18.

The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.

C Kitchener H, Canfell K, Gilham C, Sargent A, Roberts C, Desai M, Peto J.

Health Technol Assess. 2014 Apr;18(23):1-196. doi: 10.3310/hta18230.

19.

Cervical human papillomavirus (HPV) infection in South African women: implications for HPV screening and vaccine strategies.

Allan B, Marais DJ, Hoffman M, Shapiro S, Williamson AL.

J Clin Microbiol. 2008 Feb;46(2):740-2. Epub 2007 Oct 31.

20.

Type-specific persistence and associated risk factors of human papillomavirus infections in women living in central Italy.

Sammarco ML, Del Riccio I, Tamburro M, Grasso GM, Ripabelli G.

Eur J Obstet Gynecol Reprod Biol. 2013 Jun;168(2):222-6. doi: 10.1016/j.ejogrb.2013.01.012. Epub 2013 Feb 8.

PMID:
23395560

Supplemental Content

Support Center